Should You Consider Colvera?
Helping You Navigate Your New Normal.
Nearly 30-50% of colorectal cancer (CRC) patients will experience a recurrence within the first three years of primary treatment.1
Colvera is intended to help detect CRC recurrence at an early stage when more treatment options are available, giving you and your healthcare provider additional information during your follow-up visits.
In a head to head study published in Cancer Medicine, Colvera detected twice the number of recurrent CRC cases compared to CEA. Of 122 patients who were tested after completion of their initial therapy, 28 patients developed a recurrent CRC confirmed by CT Scan. Colvera detected recurrence in 19 of the 28 patients compared to only 9 of 28 patients detected by CEA.1
Colvera is designed to fit into the current recurrence monitoring protocol and can be ordered and performed at the same time as CEA, providing additional information that may possibly identify recurrence before symptoms present and cancer has spread to other areas of the body.
Talk to your healthcare provider about how Colvera can become part of your monitoring routine.
- Young G., Pedersen S, Mansfield S, et al. A cross sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Medicine 2016; 5(10):2763-2772.